Clinical trials
Prostate Cancer (Adenocarcinoma) clinical trials
Below are recruiting prostate cancer (adenocarcinoma) clinical trials, each written for real people, not researchers. We’re tracking 549 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05852041RecruitingEarly Phase 1
PET-MRI scan to find prostate cancer before active surveillance
This early-phase study tests a special PET-MRI scan using rhPSMA-73 to better detect prostate cancer areas in men who would otherwise choose active surveillance. It may help doctors see where (and how much) cancer is present before deciding on treatment.
Chicago, IllinoisAges 18 years+ - NCT05832086RecruitingPhase 2
Fasting-mimicking diet to improve prostate cancer and metabolism
This trial tests whether an intermittent, fasting-like diet can help control metastatic prostate cancer and improve metabolic health in men on hormone therapy. Participants follow a specific diet plan and are monitored by the study team.
Duarte, CaliforniaAges Any age - NCT05806515RecruitingPhase 2
Carboplatin before surgery for high-risk BRCA prostate cancer
This trial tests giving the chemotherapy drug carboplatin before surgery to treat people with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene change. The goal is to shrink or control the cancer before an operation and improve outcomes.
Anchorage, AlaskaAges 18 years+ - NCT05800665RecruitingPhase 1
Study tests a new prostate cancer drug after prior hormone therapy
This Phase 1 study tests the safety, how the drug moves through the body, and whether it shows anti-cancer activity in men with advanced or metastatic prostate cancer. It is designed for people whose cancer has already been treated with certain hormone (androgen receptor) therapies.
Scottsdale, ArizonaAges 18 years+ - NCT05766371RecruitingPhase 2
Immunotherapy plus targeted radiation for advanced prostate cancer
This study combines two treatments: pembrolizumab, which helps your immune system fight cancer, and a targeted radioactive medicine (177Lu-PSMA-617) that seeks out and damages prostate cancer cells. It may help men whose prostate cancer has spread despite initial hormone therapy.
San Francisco, CaliforniaAges 18 years+ - NCT05751434RecruitingPhase 2
Exercise therapy for prostate cancer patients on active surveillance
This trial tests whether an exercise program can help men with early-stage prostate cancer who are being monitored instead of treated. If you are not very active now, you may be able to join a structured exercise plan to see if it improves your health and cancer signs.
Durate, CaliforniaAges 18 years+ - NCT05720130RecruitingPhase 1/Phase 2
Study drug for advanced prostate cancer found on PSMA scans
This trial tests [212Pb]Pb-ADVC001, a radiotherapy-like cancer treatment, in people with advanced prostate cancer that shows up on a special PSMA scan. It aims to find the safest dose and see whether it helps shrink or control metastatic cancer.
Brisbane, QueenslandAges 18 years+ - NCT05726292RecruitingPhase 2
Enzalutamide plus relacorilant versus placebo for high-risk prostate cancer
This study tests whether adding relacorilant to enzalutamide (a hormone-blocking treatment) helps control high-risk localized prostate cancer better than enzalutamide plus a dummy pill. It may help prevent the cancer from growing or spreading by targeting a hormone pathway in addition to standard treatment.
Chicago, IllinoisAges 18 years+ - NCT05710380Recruiting
MRI scans to guide biopsy for prostate cancer diagnosis
This study tests whether special MRI “risk maps” can help doctors better identify suspicious areas in the prostate during diagnosis. If you’re having an MRI followed by an MRI-guided biopsy, this may help improve how the biopsy targets areas of concern.
Chicago, IllinoisAges 18 years+ - NCT05691465RecruitingPhase 2
Radiation drug for metastatic prostate cancer with neuroendocrine cells
This Phase 2 study tests whether a radioactive medicine called lutetium Lu 177 dotatate is safe and effective for metastatic prostate cancer that has neuroendocrine features. It also checks whether patients’ scans show the cancer absorbs the drug (a requirement to start treatment).
Duarte, CaliforniaAges 18 years+ - NCT05665738Recruiting
Two high-dose radiation treatments for early prostate cancer
This trial tests a shorter course of high-dose radiation therapy for prostate cancer that hasn't spread. It aims to make treatment more convenient while keeping it effective.
San Francisco, CaliforniaAges 18 years+ - NCT05616650RecruitingPhase 2
Targeted radiation for one prostate tumor spot
This Phase 2 study tests a focused radiation approach using stereotactic body radiation therapy (SBRT) for people with one prostate tumor visible on imaging. It aims to treat a single tumor area while limiting treatment to the rest of the prostate.
Bethesda, MarylandAges 18–120 - NCT05610852Recruiting
Surgery through the bladder opening versus focused ultrasound for prostate cancer
This trial compares two ways to treat early prostate cancer: a single small surgery through the bladder versus high-intensity focused ultrasound (HIFU). It aims to see which approach works better while keeping side effects and recovery acceptable.
Cleveland, OhioAges 19 years+ - NCT05570994Enrolling by invitationPhase 1/Phase 2
PSMA-targeted radioactive drug for advanced prostate cancer
This Phase 1/2 study tests a radioactive treatment that targets PSMA, a protein often found on prostate cancer cells. It’s for men whose prostate cancer has worsened despite hormone-blocking pills like abiraterone or enzalutamide, aiming to help shrink or control the disease.
Vancouver, British ColumbiaAges 18 years+ - NCT03833921RecruitingPhase 2
Testing abiraterone and prednisone for metastatic prostate cancer by race
This trial studies how well abiraterone (a hormone-blocking medicine) plus prednisone (a steroid) works in people with metastatic, hormone-sensitive prostate cancer. It also looks at whether results differ by race/ethnicity and other health factors.
Houston, TexasAges 18 years+ - NCT05519449RecruitingPhase 1
Testing a PSMA-targeting treatment for advanced prostate cancer
This Phase 1 trial tests JANX007 in men with metastatic castration-resistant prostate cancer (cancer that keeps growing despite standard hormone treatment). It aims to find a safe dose and see whether the treatment can shrink tumors or slow progression.
Birmingham, AlabamaAges 18–100 - NCT05530655RecruitingEarly Phase 1
Finding the best lisinopril dose to prevent urine side effects
This early study tests which dose of lisinopril works best to help prevent urinary toxicity (urine/burning/urinary side effects) after radiation treatment for prostate cancer. If it’s effective for you, it could make radiation easier to tolerate.
Rochester, New YorkAges 18–70 - NCT05521412RecruitingPhase 1/Phase 2
PSMA-targeted radioligand for advanced prostate cancer
This Phase 1/2 trial tests a PSMA-targeted radioligand treatment (a drug that delivers radiation to prostate cancer cells) in men with metastatic castration-resistant prostate cancer that has gotten worse despite standard hormone therapies. It’s designed to see how the treatment works and whether it can help shrink or control cancer, while also studying safety and dosing.
Melbourne, VictoriaAges 18 years+ - NCT05478694Recruiting
Focal ablation outcomes for prostate cancer
This study looks at how well a targeted procedure (“focal ablation,” which destroys only the cancer area) works for certain men with prostate cancer that is limited to the prostate. It may help doctors understand which people benefit most and what outcomes to expect.
Dallas, TexasAges 18–90 - NCT05422911RecruitingPhase 2
Abiraterone, enzalutamide, or apalutamide for early castration prostate cancer
This Phase 2 trial tests whether abiraterone, enzalutamide, or apalutamide can work better (or differently) in men with prostate cancer that is considered “castration-sensitive.” It compares these hormone-blocking treatments to find an approach that controls the cancer more effectively and safely.
Los Angeles, CaliforniaAges 18 years+ - NCT05454488RecruitingPhase 2
Study focal freezing for intermediate-risk prostate cancer
This trial tests whether freezing only the cancer area in the prostate (focal cryotherapy) can control intermediate-risk prostate cancer. It aims to limit treatment to one tumor focus while closely checking results with targeted and follow-up testing.
Houston, TexasAges 18 years+ - NCT05413850RecruitingPhase 1/Phase 2
Lu-177 PSMA drug study for advanced prostate cancer
This early-stage study tests a radioactive prostate cancer medicine that targets PSMA (a protein on prostate cancer cells). It aims to see how well the treatment works and how safe it is for men whose cancer has spread and shows PSMA on a scan.
Miami, FloridaAges 18 years+ - NCT05328505Recruiting
Imaging-guided radiation for prostate cancer that came back
This trial tests whether a special scan (PSMA PET) can help doctors aim and adjust radiation more precisely when prostate cancer returns after surgery. It may help by increasing dose to areas that look involved while lowering dose to uninvolved pelvic areas.
London, OntarioAges 18 years+ - NCT05334069Recruiting
Blood test study for early cancer detection in patients
This study collects blood from people with cancer and people without cancer (or with possible cancer) to test whether new blood tests can detect cancer earlier. Your blood samples help researchers evaluate how well these tests work.
Anchorage, AlaskaAges 40–75
Hear when a new Prostate Cancer (Adenocarcinoma) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate cancer (adenocarcinoma)?
- Yes. Clin2 currently lists 549 recruiting prostate cancer (adenocarcinoma) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer (adenocarcinoma) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer (adenocarcinoma) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.